Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants

N/ANo Longer AvailableNCT04221412

Janssen Sciences Ireland UC

Overview

The purpose of this pre-approval access program is to provide treatment to immunocompromised participants with serious/life-threatening diseases or conditions (Respiratory Syncytial Virus \[RSV\] infection) and to collect the safety data to understand the safety profile of JNJ-53718678.

Study Type

EXPANDED_ACCESS

Conditions

Respiratory Syncytial Virus

Interventions

JNJ-53718678DRUG

JNJ-53718678 will be administered as directed by treating physician.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.